PROCEPT BIOROBOTICS CORP (PRCT) Stock Fundamental Analysis

NASDAQ:PRCT • US74276L1052

27.79 USD
-0.3 (-1.07%)
At close: Feb 13, 2026
27.75 USD
-0.04 (-0.14%)
After Hours: 2/13/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Overall PRCT gets a fundamental rating of 4 out of 10. We evaluated PRCT against 185 industry peers in the Health Care Equipment & Supplies industry. PRCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PRCT shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • PRCT had negative earnings in the past year.
  • In the past year PRCT has reported a negative cash flow from operations.
  • In the past 5 years PRCT always reported negative net income.
  • PRCT had a negative operating cash flow in each of the past 5 years.
PRCT Yearly Net Income VS EBIT VS OCF VS FCFPRCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • PRCT has a Return On Assets of -16.53%. This is comparable to the rest of the industry: PRCT outperforms 55.14% of its industry peers.
  • Looking at the Return On Equity, with a value of -22.24%, PRCT is in the better half of the industry, outperforming 60.54% of the companies in the same industry.
Industry RankSector Rank
ROA -16.53%
ROE -22.24%
ROIC N/A
ROA(3y)-23.82%
ROA(5y)-26.26%
ROE(3y)-34.89%
ROE(5y)-42.8%
ROIC(3y)N/A
ROIC(5y)N/A
PRCT Yearly ROA, ROE, ROICPRCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • The Gross Margin of PRCT (64.55%) is better than 68.65% of its industry peers.
  • In the last couple of years the Gross Margin of PRCT has grown nicely.
  • PRCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.87%
GM growth 5YN/A
PRCT Yearly Profit, Operating, Gross MarginsPRCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • PRCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PRCT has more shares outstanding than it did 1 year ago.
  • PRCT has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, PRCT has an improved debt to assets ratio.
PRCT Yearly Shares OutstandingPRCT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRCT Yearly Total Debt VS Total AssetsPRCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • PRCT has an Altman-Z score of 6.35. This indicates that PRCT is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 6.35, PRCT belongs to the best of the industry, outperforming 83.78% of the companies in the same industry.
  • PRCT has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of PRCT (0.14) is better than 62.70% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z 6.35
ROIC/WACCN/A
WACC10.01%
PRCT Yearly LT Debt VS Equity VS FCFPRCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 8.44 indicates that PRCT has no problem at all paying its short term obligations.
  • PRCT has a better Current ratio (8.44) than 89.73% of its industry peers.
  • A Quick Ratio of 7.20 indicates that PRCT has no problem at all paying its short term obligations.
  • PRCT has a better Quick ratio (7.20) than 89.73% of its industry peers.
Industry RankSector Rank
Current Ratio 8.44
Quick Ratio 7.2
PRCT Yearly Current Assets VS Current LiabilitesPRCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • PRCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.54%, which is quite impressive.
  • PRCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 50.07%.
  • The Revenue has been growing by 105.20% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5%
Revenue 1Y (TTM)50.07%
Revenue growth 3Y86.75%
Revenue growth 5Y105.2%
Sales Q2Q%42.76%

3.2 Future

  • Based on estimates for the next years, PRCT will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.88% on average per year.
  • The Revenue is expected to grow by 26.01% on average over the next years. This is a very strong growth
EPS Next Y12.5%
EPS Next 2Y15.69%
EPS Next 3Y18%
EPS Next 5Y15.88%
Revenue Next Year46.32%
Revenue Next 2Y37.63%
Revenue Next 3Y33.25%
Revenue Next 5Y26.01%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
PRCT Yearly Revenue VS EstimatesPRCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M
PRCT Yearly EPS VS EstimatesPRCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PRCT. In the last year negative earnings were reported.
  • Also next year PRCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRCT Price Earnings VS Forward Price EarningsPRCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRCT Per share dataPRCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PRCT's earnings are expected to grow with 18.00% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.69%
EPS Next 3Y18%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PRCT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PROCEPT BIOROBOTICS CORP

NASDAQ:PRCT (2/13/2026, 8:00:00 PM)

After market: 27.75 -0.04 (-0.14%)

27.79

-0.3 (-1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-04
Earnings (Next)02-24
Inst Owners106.65%
Inst Owner Change1.37%
Ins Owners4.23%
Ins Owner Change10.04%
Market Cap1.55B
Revenue(TTM)299.91M
Net Income(TTM)-84.58M
Analysts82
Price Target53.81 (93.63%)
Short Float %12.33%
Short Ratio5.1
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.37%
Min EPS beat(2)9.47%
Max EPS beat(2)17.27%
EPS beat(4)3
Avg EPS beat(4)8.01%
Min EPS beat(4)-4.69%
Max EPS beat(4)17.27%
EPS beat(8)6
Avg EPS beat(8)5.92%
EPS beat(12)8
Avg EPS beat(12)3.91%
EPS beat(16)10
Avg EPS beat(16)4.32%
Revenue beat(2)2
Avg Revenue beat(2)1.27%
Min Revenue beat(2)0.93%
Max Revenue beat(2)1.61%
Revenue beat(4)4
Avg Revenue beat(4)1.49%
Min Revenue beat(4)0.18%
Max Revenue beat(4)3.23%
Revenue beat(8)8
Avg Revenue beat(8)3.05%
Revenue beat(12)11
Avg Revenue beat(12)2.51%
Revenue beat(16)15
Avg Revenue beat(16)5.35%
PT rev (1m)0%
PT rev (3m)-19.07%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.37%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.21%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.18
P/FCF N/A
P/OCF N/A
P/B 4.08
P/tB 4.09
EV/EBITDA N/A
EPS(TTM)-1.53
EYN/A
EPS(NY)-1.16
Fwd EYN/A
FCF(TTM)-1.43
FCFYN/A
OCF(TTM)-1.27
OCFYN/A
SpS5.37
BVpS6.81
TBVpS6.79
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.53%
ROE -22.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.55%
FCFM N/A
ROA(3y)-23.82%
ROA(5y)-26.26%
ROE(3y)-34.89%
ROE(5y)-42.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.87%
GM growth 5YN/A
F-Score6
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 141.51%
Cap/Sales 2.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.44
Quick Ratio 7.2
Altman-Z 6.35
F-Score6
WACC10.01%
ROIC/WACCN/A
Cap/Depr(3y)279.88%
Cap/Depr(5y)173.09%
Cap/Sales(3y)8%
Cap/Sales(5y)5.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5%
EPS Next Y12.5%
EPS Next 2Y15.69%
EPS Next 3Y18%
EPS Next 5Y15.88%
Revenue 1Y (TTM)50.07%
Revenue growth 3Y86.75%
Revenue growth 5Y105.2%
Sales Q2Q%42.76%
Revenue Next Year46.32%
Revenue Next 2Y37.63%
Revenue Next 3Y33.25%
Revenue Next 5Y26.01%
EBIT growth 1Y13.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year60.23%
EBIT Next 3Y32.28%
EBIT Next 5Y29.2%
FCF growth 1Y36.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.44%
OCF growth 3YN/A
OCF growth 5YN/A

PROCEPT BIOROBOTICS CORP / PRCT FAQ

What is the fundamental rating for PRCT stock?

ChartMill assigns a fundamental rating of 4 / 10 to PRCT.


What is the valuation status for PRCT stock?

ChartMill assigns a valuation rating of 0 / 10 to PROCEPT BIOROBOTICS CORP (PRCT). This can be considered as Overvalued.


What is the profitability of PRCT stock?

PROCEPT BIOROBOTICS CORP (PRCT) has a profitability rating of 2 / 10.


What is the financial health of PROCEPT BIOROBOTICS CORP (PRCT) stock?

The financial health rating of PROCEPT BIOROBOTICS CORP (PRCT) is 6 / 10.